JP7471232B2 - Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 - Google Patents

Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 Download PDF

Info

Publication number
JP7471232B2
JP7471232B2 JP2020560316A JP2020560316A JP7471232B2 JP 7471232 B2 JP7471232 B2 JP 7471232B2 JP 2020560316 A JP2020560316 A JP 2020560316A JP 2020560316 A JP2020560316 A JP 2020560316A JP 7471232 B2 JP7471232 B2 JP 7471232B2
Authority
JP
Japan
Prior art keywords
cancer
compound
mmol
pharma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522276A (ja
JP2021522276A5 (enExample
Inventor
エリック フィッシャー，
ナサナエル エス． グレイ，
ラドスロー ノワク，
キャサリン ドノヴァン，
ティンフー チャン，
ヤオ リウ，
Original Assignee
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド filed Critical ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド
Publication of JP2021522276A publication Critical patent/JP2021522276A/ja
Publication of JP2021522276A5 publication Critical patent/JP2021522276A5/ja
Priority to JP2024004034A priority Critical patent/JP7838004B2/ja
Application granted granted Critical
Publication of JP7471232B2 publication Critical patent/JP7471232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020560316A 2018-04-30 2019-04-30 Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤 Active JP7471232B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024004034A JP7838004B2 (ja) 2018-04-30 2024-01-15 Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664592P 2018-04-30 2018-04-30
US62/664,592 2018-04-30
PCT/US2019/029778 WO2019213005A1 (en) 2018-04-30 2019-04-30 Small molecule degraders of polybromo-1 (pbrm1)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024004034A Division JP7838004B2 (ja) 2018-04-30 2024-01-15 Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤

Publications (3)

Publication Number Publication Date
JP2021522276A JP2021522276A (ja) 2021-08-30
JP2021522276A5 JP2021522276A5 (enExample) 2022-05-09
JP7471232B2 true JP7471232B2 (ja) 2024-04-19

Family

ID=68386081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560316A Active JP7471232B2 (ja) 2018-04-30 2019-04-30 Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤
JP2024004034A Active JP7838004B2 (ja) 2018-04-30 2024-01-15 Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024004034A Active JP7838004B2 (ja) 2018-04-30 2024-01-15 Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤

Country Status (6)

Country Link
US (1) US11771697B2 (enExample)
EP (1) EP3787747A4 (enExample)
JP (2) JP7471232B2 (enExample)
AU (1) AU2019261938B2 (enExample)
CA (1) CA3093405C (enExample)
WO (1) WO2019213005A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3121667A1 (en) * 2018-09-30 2020-04-02 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Isoindoline compound, preparation method, pharmaceutical composition and use thereof
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
EP4054724A4 (en) * 2019-10-28 2023-12-27 C4 Therapeutics, Inc. BIFUNCTIONAL CONNECTIONS
CN114728936A (zh) * 2019-10-29 2022-07-08 豪夫迈·罗氏有限公司 用于治疗癌症的双功能化合物
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
CA3167166A1 (en) * 2020-01-10 2021-07-15 Amgen Inc. Smarca2-vhl degraders
EP4192504A4 (en) * 2020-08-07 2025-04-16 Cornell University THERAPEUTIC HARDENING PRO-COMPOUNDS FOR THE TARGETED DEGRADATION OF BET-DOMAIN PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US12552775B2 (en) * 2020-11-20 2026-02-17 Foghorn Therapeutics Inc. Compounds and uses thereof
US20240024488A1 (en) * 2020-11-20 2024-01-25 Foghorn Therapeutics Inc. Compounds and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
MX2023012981A (es) * 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック， インコーポレイテッド Ｂｒｍの調節に使用するためのフェノール誘導体
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic glutarimide-modified cervalon-binding agents
PE20260307A1 (es) 2023-06-14 2026-02-11 Astrazeneca Ab Degradadores de smarca2 y usos de estos
IL325247A (en) 2023-06-14 2026-02-01 Astrazeneca Ab History of 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-8,3-diazabicyclo[3.2.1]octane as a protacs from SMARCA2 joints for cancer treatment
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
CN122070278A (zh) * 2024-09-19 2026-05-19 标新生物医药科技(上海)有限公司 含有芳基取代杂芳基的双功能蛋白降解剂及其应用
WO2026120044A1 (en) 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510851A (ja) 2015-02-25 2018-04-19 ジェネンテック， インコーポレイテッド 治療用ピリダジン化合物およびその使用
JP2021520350A (ja) 2018-04-01 2021-08-19 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｂｒｍ標的化化合物および関連使用方法
JP2021520372A (ja) 2018-04-26 2021-08-19 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AU2017246452C1 (en) * 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
ES2857743T3 (es) 2016-09-13 2021-09-29 Univ Michigan Regents 1,4-diazepinas fusionadas como degradadores de proteína BET
WO2019023149A1 (en) * 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510851A (ja) 2015-02-25 2018-04-19 ジェネンテック， インコーポレイテッド 治療用ピリダジン化合物およびその使用
JP2021520350A (ja) 2018-04-01 2021-08-19 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｂｒｍ標的化化合物および関連使用方法
JP2021520372A (ja) 2018-04-26 2021-08-19 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体

Also Published As

Publication number Publication date
US20210038599A1 (en) 2021-02-11
CA3093405C (en) 2025-06-17
EP3787747A4 (en) 2022-01-12
EP3787747A1 (en) 2021-03-10
US11771697B2 (en) 2023-10-03
JP2021522276A (ja) 2021-08-30
WO2019213005A1 (en) 2019-11-07
JP7838004B2 (ja) 2026-03-31
AU2019261938B2 (en) 2024-06-13
CA3093405A1 (en) 2019-11-07
AU2019261938A1 (en) 2020-09-24
JP2024041923A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
JP7838004B2 (ja) Ｐｏｌｙｂｒｏｍｏ－１（ｐｂｒｍ１）の小分子分解剤
JP7720833B2 (ja) Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
US20260027217A1 (en) Degraders that target alk and therapeutic uses thereof
AU2019294835A1 (en) Ligands to cereblon (CRBN)
US20220177466A1 (en) Degraders of kelch-like ech-associated protein 1 (keap1)
JP7626721B2 (ja) 小分子標的ブロモ／アセチルタンパク質およびその使用
EP3813834A1 (en) New crbn modulators
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
US20220387604A1 (en) Selective dual histone deacetylase 6/8 (hdac6/8) degraders and methods of use thereof
EP4367115A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof
JP7667742B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
US20220033402A1 (en) Macrocyclic inhibitors of alk, trka, trkb, and ros1
AU2021251690B2 (en) Arginine methyltransferase 5 (PRMT5) degraders and uses thereof
US20240374737A1 (en) Erk5 degraders and uses thereof
WO2026024772A2 (en) Oxynitidine derivatives as tyrosyl dna phosphodiesterase inhibitors and radiosensitizers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230720

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240409

R150 Certificate of patent or registration of utility model

Ref document number: 7471232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150